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Abstract 
 
Long chain (LC) polyunsaturated fatty acids (PUFA) are major components of cell membrane 
phospholipids (PL) and serve as precursors for numerous bioactive lipid derivatives.  Fatty acids 
(FA) are routinely analyzed in biological samples to assess composition of tissues, cells, and 
lipid fractions.  In human studies, serum or plasma is often used because of their easy 
procurement.  However, the lipid pool in serum and plasma is a mixture of triacylglycerol (TG), 
PL, cholesterol and its esters, and other components.  Herein, we report findings from a serum 
FA analysis after fractionation of polar and neutral lipids by solid phase extraction in a large 
cohort of 400 hemodialysis patients.  LC PUFA were found concentrated in the polar fraction 
compared to the total or the neutral lipid fraction.  When correlated with clinical markers of 
disease, a greater number of significant correlations were found for PUFA in polar compared to 
total or the neutral fraction.  We also observed that polar lipids are a reliable reflection of LC 
PUFA status compared to the total or neutral fractions because the latter are diluted by non-
essential FA.  The relative amounts of LC PUFA in the total and neutral fractions reflect the 
contribution of TG in blood that varies with diet, age, and physiologic state.  Our data indicate 
that LC PUFA in the polar fraction are superior indicators of bioactive FA-status than in the total 
or the neutral fraction and should be used to establish important links between PUFA status, their 
bioactive substrates in hemodialysis patients. 
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1. Introduction 
The study of fatty acid (FA) composition of tissue phospholipids (PL) is important because long 
chain (LC) polyunsaturated fatty acids (PUFA) associated with these lipids serve critical 
biological roles as the precursors for numerous bioactive lipid derivatives and in cell-to-cell 
communications[1, 2].  The PUFA-derived mediators include prostaglandins, leukotrienes, 
thromboxanes, endocannabinoids (EC), and other families of oxylipins.  In human studies, serum 
or plasma is commonly used to evaluate fatty acid status because of its availability and the FA 
composition of circulating PL is the most reliable estimate of PUFA and essential fatty acid 
status PL[3]. 
Analyses of LC PUFA are routinely performed to assess dietary status and tissue 
composition related to their biological importance.  The analysis begins with the extraction of 
lipids from the sample and in some cases isolation of lipid classes, for example, the polar lipids 
such as PL from those that are non-polar lipid compounds such as triacylglycerols (TG).  Thus 
the blood lipid pool is a mixture of TG, PL, cholesterol and its esters, and other lipid constituents 
including FA.  The FA composition of serum PL has become an acceptable indicator for 
assessing nutrition status and to predict dietary fat intakes and de novo lipid synthesis[4] but its 
importance in dialysis patients is not well established. 
It is recognized that LC n–3 PUFA, by virtue of their biochemistry and numerous derivatives, 
participate in a number of key biological processes.  An example are the oxylipin derivatives that 
participate in cell membrane physiology, cell membrane fluidity, cell signaling pathways, 
inflammation, and gene expression[1,3, 5-7].  The importance of LC n-3 PUFA to cardiovascular 
health is also of great scientific interest.  With its anti-inflammatory, anti-arrhythmic, lipid-
lowering, and anti-hypertensive effects, LC n-3 PUFA have been described in many reports to 
possess important cardioprotective benefits, especially for eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA)[8-10].  This is especially relevant for the chronic hemodialysis 
population, which has exceptionally high rates of cardiovascular disease[11]. 
Higher amounts of PUFA are recognized to be associated with PL relative to the amounts 
found in neutral lipids like TG[12].  Because LC PUFA rarely accumulate in the neutral lipid 
fraction, only serum total lipids or polar LC PUFA will be useful as clinical biomarkers in 
hemodialysis subjects, a population with a large burden of illness[13].  Similar findings have 
been noted in non-dialysis patients[13].  Because LC PUFA in the polar lipid fraction is a better 
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and more stable reflection of total LC PUFA than what is found in other glycerol lipids such as 
TG, we firmly support that when studying the biological actions of PUFA the focus of attention 
should be on the polar lipid fraction.  LC PUFA in the polar lipid fraction are subject to many 
biochemical pathways that liberate (such as by phospholipase A2) PUFA for biosynthesis of 
potent biological mediators via the cyclooxygenase (COX), lipoxygenase (LOX), EC pathways 
and others[1, 2]. 
Therefore, the overarching hypothesis of this study is that the FA composition of serum polar 
lipid fraction best represents overall PUFA status in chronic hemodialysis patients and is 
therefore a better indicator of dietary status and well-being.  The aims of this study were to 
confirm in hemodialysis patients that: 1) greater amounts of LC PUFA are found in the polar 
lipid fraction; 2) that LC PUFA in the polar fraction provide greater clinical relevance for 
essential FA status and dietary status of the subject or patient than other fractions; 3) that LC 
PUFA in the polar lipid fraction reflect more stable levels of LC PUFA than what is found in 
other glycerol lipids such as TG.  The nutrition and clinical significance of our analyses is to 
achieve the best representative appraisal of PUFA to assess diet status and disease risk. 
 
 
2. Subjects and Methods 
2.1 Study population and collection of serum samples 
The population of 10,044 individuals who participated in the Accelerated Mortality on Renal 
Replacement (ArMORR) project, a nationally representative prospective cohort study of patients 
who initiated chronic hemodialysis at one of 1,056 dialysis centers in the U.S, have been 
previously described[14].  This study was approved by the Institutional Review Board of the 
Massachusetts General Hospital, Boston, MA, ClinicalTrials.gov Identifier: NCT00505180. 
 
2.2 Lipid class fractionation  
Human serum samples were processed to determine FA composition in serum, and in neutral and 
polar lipid fractions after solid phase extraction.  100 µl was used for the total lipids analysis and 
140 µl for the polar and neutral lipid fraction analyses.  Briefly, serum lipids were extracted with 
7.5 ml chloroform/methanol (2:1, vol/vol).  For the analysis of fatty acids in the neutral and polar 
lipid fractions, solid phase extraction was used to fractionate the extracted lipids with chloroform 
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(20 ml) eluting the neutral lipid fraction and the methanol (20 ml) eluting the polar lipid fraction 
by a silica cartridge (300 mg filling, Alltech) attached to a 20 ml glass syringe[15, 16].  The 
fractions were then dried under nitrogen gas stream. 
For the measurement of fatty acids in the total lipids and the neutral lipid fraction, the 
extracted lipids were treated with 0.5 ml 0.5 N NaOH in methanol at 100oC for 20 minutes, and 
fatty acid methyl esters (FAME) prepared by esterification using boron trifluoride (BF3) in 
methanol (10% w/w, Supelco Inc. Bellefonte, PA) at 100oC using a heating block for 20 minutes 
in tightly sealed test tubes filled with nitrogen gas.  The polar lipid fraction was methylated to 
FAME directly with 10% BF3 in methanol after heating at 100oC for 10 minutes in a tightly 
sealed test tube after containing nitrogen gas.  The resulting FAME was dissolved in 100 µl 
isooctane (HPLC grade, Fisher Scientific, Pittsburg, PA) and transferred to a GC sample vial 
with insert. 
 
2.3 Gas chromatographic analysis of FAME 
The resulting FAME from the total lipids, and the neutral and polar fractions of serum were 
analyzed by gas chromatography (GC) (HP 7890A series, autosampler 7693, GC ChemStation 
Rev.B.04.03, Agilent Technologies, Palo Alto, CA) with a DB-225 column (30 m, 0.25 mm i.d., 
0.15 mm film thickness, Agilent Technologies, Palo Alto, CA) equipped with a flame ionization 
detector[15].  The oven temperature was programmed as following: initial temperature at 140oC, 
hold for 2 minutes, then ramp at 5oC/minute to reach a temperature of 180oC, hold for 12 
minutes, then ramp at 15oC/minute to 210oC, hold for 11 minutes.  Total GC run time was 35 
minutes.  Sample peaks were identified by comparison to authentic FAME standards (Nu-Chek-
Prep Inc., Elysian, MN).  Results of FAME analysis were obtained by weight percentage reports.  
Total LC n-3 PUFA were defined as the weight percentage of 20:5n-3 (EPA) + 22:5n-3 
(docosapentaenoic acid) + 22:6n-3 (DHA), and total LC n-6 PUFA as the sum of the weight 
percentage of 20:4n-6 (arachidonic acid, AA) +22:4n-6+22:5n-6.  
 
2.4 Statistical analyses 
Data for serum FA composition were expressed as the means and standard deviations.  The 
coefficient of variation (CV) was determined and the significance level between the deceased 
and the survived subject groups were calculated by the t-test procedure using SAS (version 9.3; 
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SAS Institute, Inc., Cary, NC, USA) and p values less than 0.05 were regarded as significantly 
different.  Correlation analysis between serum FA and selected clinical parameters were 
performed by the Pearson correlation procedure in SAS and p values less than 0.05 were 
regarded as significantly different. 
 
3. Results 
The 400 ArMORR subjects used for this analysis were part of a separate study that included 
100 deceased who died of sudden cardiac death during the first year on hemodialysis and 300 
patients who survived (Supplemental Table 1).  LC PUFA levels are higher in the polar fraction 
than in the total lipids (Table 1A) and neutral fraction (Table 1B).  Levels of the two most 
common LC PUFA, AA and DHA, were consistently higher in the polar fraction compared to 
total lipids or neutral fraction, as were the total n-3 PUFA, n-3 LC PUFA, and n-6 LC PUFA.  
The total n-3 PUFA were higher in the polar (4.35%) compared to 2.71% in the total lipids and 
only 0.69% in the neutral lipid fraction.  Total LC n-6 PUFA were also higher in the polar 
fraction at 11.41% compared to 8.09% in the total lipids and 5.26% in the neutral fraction.  Total 
n-3 LC PUFA were 3.99% in the polar compared to 2.15% in the total lipids and merely 0.28% 
in the neutral lipid fractions.  The ratio of LC n-6 PUFA to LC n-3 PUFA was lower in the polar 
lipid (3.06) compared to that of the total lipid (4.15) and neutral lipid fraction (8.30).  Therefore, 
LC PUFA were found concentrated in the polar fraction compared to both the neutral fraction 
and the total lipids.  The relative amounts of LC PUFA in the total lipids and neutral fraction 
reflect the contribution of TG in blood that varies with diet (amount and type of fat, caloric 
macronutrient intake), age (young versus old) and physiologic state (BMI and activity). 
Our data also show that the polar lipid fraction is a more stable reflection of LC PUFA status 
compared to the other lipid fractions because the latter are diluted by non-essential FA.  
Specifically, Tables 2 and 3 show that smaller CV values for PUFA in the polar fraction were 
observed when compared to the total lipids and neutral lipid fraction (Table 2 for subjects who 
survived and Table 3 for those who died).  Among all the FA measured in subjects who survived, 
AA of polar lipids had a CV value of 22.46 compared to 27.87 in the total lipids and 35.84 in the 
neutral fraction (Table 2).  The CV for DHA was 34.05 in the polar fraction compared to 41.43 
for the total lipids and 179.2 for the neutral fraction.  For total PUFA, the CV of polar lipid was 
only 7.51 compared to 10.50 for the total lipids and 14.91 for the neutral lipid fraction.  
8 
 
Similarly, the CV for total lipid LC PUFA (POLY) was only 7.51 for the polar fraction while 
that of the total lipid was 10.50 and that for neutral lipid was 14.91 (Table 2).  Likewise, the 
values for POLY for those who died of sudden cardiac death were 9.91, 13.87, and 19.03, 
respectively (Table 3).  Of interest with respect to n-3 PUFA status and sudden cardiac death is 
that EPA and DHA levels in the polar lipid fractions were higher in hemodialysis patients, 
regardless of whether they survived or died of sudden cardiac death (Tables 2 and 3).  Therefore, 
since these n-3 PUFA are believed to be lower in hemodialysis patients that puts them at risk for 
cardiovascular disease, a more precise measurement of their levels could be achieved by the 
polar lipid analysis of the PUFA.  Furthermore, in the polar lipid fraction, DHA and total n-3 
PUFA were higher in hemodialysis patients that were survivors.  The smaller CV values 
observed in the polar lipid fraction for AA, DHA, and total LCPUFA indicates less variability 
for the polar lipid fraction, which potentially offers more predictive power when evaluating 
nutritional status and biomarker relationships for hemodialysis patients. 
When comparing the difference in hemodialysis patient serum polar lipid fraction FA and 
clinical data between the deceased and the survived subjects, major LC PUFA species are noted 
to be significantly different between the two groups of subjects (Table 4).  In particular the polar 
lipids revealed higher levels of DHA, total PUFA (POLY), total n-6 PUFA, total n-3 PUFA, and 
lower ratio of n-6 to n-3 PUFA in subjects who survived, while the total monounsaturated fatty 
acids were higher in those who died.  The analysis of serum neutral lipid fractions FA values 
generally indicated no differences in PUFA or ratios of PUFA between hemodialysis subjects 
who survived or died (data not shown).  Thus, there are distinctive differences between subjects 
who survived and died with regard to their serum PUFA composition for the polar lipid fraction. 
A greater number of significant correlations with important clinical parameters such as blood 
pressure or blood cholesterol were found associated with primarily PUFA in the polar lipid 
fraction compared to the neutral lipid fraction or total lipids (Table 5).  The values presented in 
Table 5 include the p values identified in brackets.  Significant correlations between selected 
serum fatty acid values in the polar lipid fraction and clinical parameters were more frequently 
observed compared to the same analysis using the total lipid and neutral lipid fraction (32 in the 
polar fraction vs. 11 each in total lipid and 20 in neutral fraction).  As shown in Table 5, more 
significant correlations of FA (primarily for PUFA) in the polar lipid fraction for clinical 
parameters were found when compared to the number of the significant correlations found in the 
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total lipid and neutral lipid fraction.  The results show a robust relationship of higher PUFA in 
the chemical analysis of polar lipids compared to the FA analysis based on total lipid or neutral 
lipid fraction. 
 
 
4. Discussion 
In this investigation we found that in hemodialysis patients the polar fraction of serum lipids, 
which is rich in phospholipids, is preferentially enriched with LC PUFA [13] and is more 
strongly associated with some markers than found with the neutral fraction of PUFA.  These 
observations coincide with the general population; even though the absolute LC n-3 PUFA 
content in hemodialysis patients is generally lower compared to the common population[13].  
Recently, other investigators reported that the concentrations of saturated fatty acids in 
phospholipid of plasma were positively and n-6 PUFA inversely correlated to coronary heart 
disease risk[17]; while the concentration of trans linoleic acid in plasma phospholipids was 
associated with lowered risk of heart failure rate in a cohort of 788 matched pairs in the US male 
physicians’ study[18].  It is firmly understood that the plasma polar lipid fraction contains the 
majority of PUFA present in the blood, which reflects the endogenous fatty acid metabolism 
(deacylation and reacylation of phospholipids) as well as dietary fatty acid intake of PUFA in an 
individual[19].  More importantly, PUFA content in circulating phospholipids approximates that 
of cell membrane phospholipids and thus, plasma/serum phospholipids may well represent the 
functional lipid pool[20].  Higher amounts of PUFA are indeed well recognized to be associated 
with the phospholipid faction compared to the amounts found in neutral lipids like TG[12].  
Another example to support our position is that AA has been shown to be highly enriched in the 
phospholipid (4%) fraction relative to the TG fraction (<1%)[12]. 
Herein we have demonstrated that LC PUFA are concentrated in the polar lipid fraction and 
the distribution of their values are in a stable, uniform range, implying greater value in predicting 
and assessing the essential fatty acid status in hemodialysis patients compared to the amounts 
found in the total lipid and the neutral lipid fraction.  It is therefore logical to adopt the position 
that PUFA in the polar lipids possess greater biological and physiological significance compared 
to PUFA in other lipid fractions.  For example, Holub et al. reported that phospholipid 
composition of serum or plasma is a valid biochemical marker for evaluating the status of 
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various fatty acids in human physiology[21].  LC PUFA are precursors of an entire spectra of 
biologically active compounds called oxylipins[1] and endocannabinoids[22].  When combined 
with an amide group, these PUFA will form the endocannabinoid class of lipid derivatives.  
Through the action of biochemical pathways that liberate LC PUFA in the PL fraction (such as 
by PLA2), the LC PUFA can be further converted to biologically active compounds by the COX 
and LOX pathways to yield many potent biological mediators.  In addition, it has been well 
established that phospholipids play important roles as lipids constituting the cell membrane and 
in plasma lipoproteins, and play critical roles in the mobilization of cholesterol from the cell 
membrane and the regulation of genetic functions and protein metabolism[23, 24].  The clinical 
significance of the n-3 LC PUFA in cardiac health is documented[25] but their role as precursors 
of oxylipins and inflammation is growing[1].  In addition to its application in lowering disease 
risk, defining LC n–3 PUFA content in blood is also important because it helps determine the 
risk level associated with the LC n–3 PUFA status in a particular individual or a population so 
that corresponding measures could be taken to adjust any imbalance in LC n-3 PUFA status.  
The connection between informative blood analysis of FA and cardiovascular diseases is 
supported by analysis of PL in polar lipids.  Our premise is reinforced by the association of LC 
n-3 PUFA and the ratio of n-6/n-3with hypertension [26] and diastolic blood pressure inversely 
related to monounsaturated fatty acids in 4680 adults [27].  Understanding the relationships of 
PUFA to disease should be based on the most accurate assessment of lipid class of blood samples 
for lipid analysis.  In this case the polar lipids are not diluted with fatty acids of lower 
significance to the biomarkers that are most relevant to inflammation and blood pressure and diet 
assessment.  Studies on oxylipins and endocannabinoids will require greater attention to specific 
lipid types such as phospholipids for linking theses substrates to markers of human disease risk 
[1, 22]. 
Our results support the position that in hemodialysis patients, as in the general population, 
the polar lipid fraction of circulating fatty acids is the best fraction of fatty acid containing lipids 
with which to assess nutrition, health, and disease status.  Further, as described, many clinical 
studies have relied on the fatty acid analysis of tissue phospholipids to determine dietary status 
or disease risk. Because of consistently higher levels of both AA and DHA, ratios of LC/SM, or 
other ratios that reflect overall status of LC PUFA, analysis of serum polar lipid LC PUFA could 
be the most useful indicators of general condition and disease risk.  The polar lipid fraction is 
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important with regard to substrates for oxylipins and endocannabinoids associated with 
inflammation and systemic energy metabolism [1, 2, 22]. 
In summary, our data advocate that LC PUFA in the serum polar lipid fraction is a superior 
indicator of nutrition status and disease risk compared to total lipids or the neutral lipid fraction 
in the hemodialysis patient.  Our study has some limitations, it was not possible to extensively 
investigate an exhaustive set of health and disease related clinical assessments with fatty acids in 
different lipid classes.  Given our findings, this would be a logical approach in the dialysis 
patient.  Furthermore, future study should also focus the work and resources on the polar fraction 
of blood lipids to produce and maximize meaningful findings for understanding 
endocannabinoids and appetite as well as oxylipins and inflammation.  This new information can 
be a used to measure and establish valid links between PUFA status for biomarkers to reduce 
disease risk in hemodialysis patients. 
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Table 1. PUFA serum values in the polar lipid compared to the total lipid and neutral lipid 
fraction of all subjects 
 
A: Polar vs. total lipids 
 
Fatty acids Polar (n = 400)   Total (n = 400) T-test p value Mean SD CV   Mean SD CV 
18: 2n-6 18.65 2.78 15  28.50 4.06 14 <.0001 
20: 4n-6 10.48 2.48 24 7.60 2.20 29 <.0001 
22: 6n-3 2.87 1.10 38 1.43 0.65 45 <.0001 
TN6 32.41 2.67 8 38.23 4.45 12 <.0001 
TN3 4.35 1.43 33 2.71 0.97 36 <.0001 
TN6/TN3 8.09 2.28 28  15.58 5.74 37 <.0001 
N6LC 11.41 2.61 23 8.09 2.30 28 <.0001 
N3LC 3.99 1.45 36 2.15 0.96 45 <.0001 
LCN6/N3 3.06 0.80 26  4.15 1.55 37 <.0001 
LCPUFA 15.39 3.46 22 10.24 2.85 28 <.0001 
LC/SM 0.26 0.07 26 0.18 0.06 32 <.0001 
ED/SM 0.05 0.02 45 0.03 0.02 54 <.0001 
AA/SM 0.17 0.05 26   0.14 0.05 33 <.0001 
 
B: Polar vs. neutral fraction 
 
Fatty acids Polar (n = 400)   Neutral (n = 400) T-test p value Mean SD CV   Mean SD CV 
18: 2n-6 18.65 2.78 15  33.42 5.40 16 <.0001 
20: 4n-6 10.48 2.48 24 5.25 1.96 37 <.0001 
22: 6n-3 2.87 1.10 38 0.21 0.40 191 <.0001 
TN6 32.41 2.67 8 38.74 6.34 16 <.0001 
TN3 4.35 1.43 33 0.69 0.85 124 <.0001 
TN6/TN3 8.09 2.28 28  40.19 17.29 43 <.0001 
N6LC 11.41 2.61 23 5.26 1.96 37 <.0001 
N3LC 3.99 1.45 36 0.28 0.64 230 <.0001 
LCN6/N3 3.06 0.80 26  8.30 3.69 45 <.0001 
LCPUFA 15.39 3.46 22 5.53 2.11 38 <.0001 
LC/SM 0.26 0.07 26 0.10 0.05 45 <.0001 
ED/SM 0.05 0.02 45 0.01 0.01 232 <.0001 
AA/SM 0.17 0.05 26 0.10 0.04 44 <.0001 
Abbreviations: CV, coefficient of variation; AA, 20:4n-6; TOTS, total saturated; TOTM, total monounsaturated; 
POLY, total polyunsaturated; TN6, total n-6 PUFA; TN3, total n-3 PUFA; N6LC, total long-chain n-6 PUFA (20C 
and 22C); N3LC, total long-chain n-3 PUFA (20C and 22C); LCPUFA, the sum of N6LC and N3LC; LC/SM, 
LCPUFA/(TOTS + TOTM); ED/SM, (EPA + DHA)/(TOTS + TOTM);  AA/SM, AA/(TOTS + TOTM).  
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Table 2. Serum fatty acid composition (wt %) in hemodialysis survivors 
Fatty acids Total lipids (n = 300)   Neutral lipids (n = 300)   Polar lipids (n = 300) Mean SD CV   Mean SD CV   Mean SD CV 
14: 0 0.50 0.31 61.99   0.46 0.55 118.2   0.27 0.18 67.37 
14: 1n-5 0.0002 0.003 1732  ND    ND   
15: 0 0.11 0.09 82.97  ND   0.02 0.05 247.9 
16: 0 20.13 1.79 8.880  17.84 2.17 12.14 22.25 1.98 8.880 
trans-16: 1 0.52 0.14 26.55  ND   0.24 0.14 60.39 
16: 1n-7 1.64 0.60 36.50  2.24 0.86 38.44 0.76 0.41 54.35 
17: 0 0.27 0.07 25.67  0.01 0.05 578.1 0.37 0.07 17.85 
18: 0 6.89 1.34 19.47  4.56 2.39 52.43 17.57 2.56 14.56 
18: 1n-9 23.80 3.08 12.96  28.39 3.88 13.65 15.56 3.25 20.91 
18: 1n-7 2.34 0.42 17.81  2.11 0.48 22.92 2.37 0.34 14.24 
18: 2n-6 28.65 3.88 13.56  33.67 5.15 15.28 18.66 2.80 14.98 
18: 3n-6 0.34 0.21 61.36  ND   0.03 0.08 250.8 
18: 3n-3 0.57 0.23 40.90  0.44 0.47 107.4 0.37 0.22 59.35 
20: 0 0.004 0.02 504.9  0.0009 0.02 1732 0.03 0.06 247.3 
20: 1n-9 0.12 0.12 93.22  0.01 0.10 832.8 0.10 0.12 122.8 
20: 2n-6 0.33 0.11 34.53  0.01 0.05 762.7 0.47 0.10 21.56 
20: 3n-6 0.97 0.43 44.92  0.06 0.23 366.6 1.86 0.77 41.62 
20: 4n-6 7.81 2.17 27.87  5.39 1.93 35.84 10.81 2.43 22.46 
20: 5n-3 0.33 0.29 89.60  0.08 0.28 367.1 0.37 0.36 96.74 
22: 0 ND    0.002 0.03 1732 0.16 0.17 105.2 
22: 1n-9 ND    ND   0.04 0.11 234.4 
22: 4n-6 0.28 0.08 29.42  0.004 0.04 1178 0.49 0.12 23.70 
22: 5n-6 0.23 0.11 49.73  ND   0.45 0.16 35.72 
22: 5n-3 0.42 0.12 29.28  ND   0.79 0.19 24.51 
22: 6n-3 1.50 0.62 41.43  0.22 0.40 179.2 3.01 1.02 34.05 
24: 0 0.02 0.05 249.8  ND   0.08 0.13 151.3 
24: 1n-9 0.09 0.09 101.7   ND   0.27 0.22 82.25 
TOTS 27.91 2.44 8.750  22.87 3.77 16.49 40.76 2.84 6.960 
TOTM 28.51 3.54 12.40  32.76 4.34 13.23 19.34 3.78 19.52 
POLY 41.40 4.35 10.50  39.87 5.95 14.91 37.29 2.80 7.510 
TN6 38.59 4.08 10.58  39.14 5.96 15.24 32.76 2.45 7.490 
TN3 2.82 0.90 31.83  0.73 0.83 113.0 4.53 1.31 28.87 
N6LC 8.31 2.27 27.27  5.40 1.93 35.73 11.74 2.55 21.71 
N3LC 2.25 0.90 40.04  0.30 0.61 206.1 4.16 1.33 32.06 
LCPUFA 10.56 2.79 26.40  5.70 2.08 36.48 15.90 3.30 20.74 
LC/SM 0.19 0.06 30.41  0.11 0.05 43.22 0.27 0.06 23.41 
ED/SM 0.03 0.02 49.01  0.01 0.01 210.3 0.06 0.02 39.25 
AA/SM 0.14 0.04 31.69   0.10 0.04 42.56 0.18 0.04 24.82 
Abbreviations: AA, 20:4n-6; TOTS, total saturated; TOTM, total monounsaturated; POLY, total polyunsaturated; 
TN6, total n-6 PUFA; TN3, total n-3 PUFA; N6LC, total long-chain n-6 PUFA (20C and 22C); N3LC, total long-
chain n-3 PUFA (20C and 22C); LCPUFA, the sum of N6LC and N3LC; LC/SM, LCPUFA/(TOTS + TOTM); 
ED/SM, (EPA + DHA)/(TOTS + TOTM); AA/SM, AA/(TOTS + TOTM); ND, not detected, below detection limit 
of 10 ng/peak.   
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Table 3. Serum fatty acid composition (wt %) in hemodialysis patients who died of sudden cardiac death 
Fatty acids Total lipids (n = 100)  Neutral lipids (n = 100)  Polar lipids (n = 100) Mean SD CV  Mean SD CV  Mean SD CV 
14: 0 0.52 0.33 63.34 0.41 0.60 146.3 0.31 0.21 66.80 
14: 1n-5 0.001 0.01 1000 0.002 0.02 1000 ND   
15: 0 0.09 0.10 110.2 ND   0.03 0.06 229.6 
16: 0 20.73 2.08 10.03 18.31 2.43 13.28 22.89 2.31 10.07 
trans-16: 1 0.52 0.14 27.86 ND   0.25 0.15 59.70 
16: 1n-7 1.75 0.72 41.32 2.33 1.04 44.67 0.85 0.42 49.06 
17: 0 0.26 0.10 39.99 0.02 0.08 456.2 0.37 0.07 18.00 
18: 0 6.91 1.37 19.82 4.99 2.41 48.26 17.32 2.39 13.82 
18: 1n-9 24.89 3.81 15.32 29.24 4.34 14.84 16.99 3.65 21.49 
18: 1n-7 2.39 0.33 13.70 2.03 0.66 32.70 2.39 0.34 14.06 
18: 2n-6 28.08 4.55 16.19 32.67 6.05 18.52 18.63 2.76 14.84 
18: 3n-6 0.33 0.25 76.33 ND   0.04 0.10 249.3 
18: 3n-3 0.53 0.23 44.35 0.34 0.43 125.9 0.35 0.23 64.68 
20: 0 0.01 0.02 420.3 ND   0.02 0.06 306.7 
20: 1n-9 0.13 0.11 88.46 0.02 0.08 478.7 0.11 0.13 114.9 
20: 2n-6 0.36 0.17 47.61 0.01 0.06 574.2 0.48 0.12 24.44 
20: 3n-6 0.94 0.45 47.85 0.05 0.14 298.4 1.84 0.73 39.68 
20: 4n-6 6.99 2.16 30.88 4.83 1.99 41.14 9.48 2.37 25.03 
20: 5n-3 0.28 0.38 135.6 0.05 0.36 755.4 0.31 0.47 150.7 
22: 0 ND   ND   0.14 0.17 114.1 
22: 1n-9 ND   0.003 0.03 1000 0.05 0.10 199.3 
22: 4n-6 0.26 0.11 44.21 ND   0.49 0.13 26.06 
22: 5n-6 0.20 0.13 64.27 ND   0.42 0.17 40.19 
22: 5n-3 0.35 0.16 44.89 ND   0.69 0.18 25.74 
22: 6n-3 1.22 0.67 55.08 0.16 0.39 240.3 2.47 1.21 49.16 
24: 0 0.02 0.04 244.7 ND   0.07 0.13 186.4 
24: 1n-9 0.08 0.10 117.8  ND    0.30 0.27 91.59 
TOTS 28.53 2.94 10.32 23.72 4.19 17.68 41.15 3.34 8.120 
TOTM 29.75 4.31 14.50 33.62 4.66 13.87 20.93 4.18 19.96 
POLY 39.53 5.48 13.87 38.11 7.25 19.03 35.21 3.49 9.910 
TN6 37.15 5.29 14.23 37.55 7.26 19.33 31.38 3.00 9.580 
TN3 2.38 1.10 46.16 0.55 0.91 163.7 3.83 1.65 43.06 
N6LC 7.45 2.29 30.71 4.83 1.99 41.14 10.39 2.55 24.49 
N3LC 1.86 1.07 57.85 0.21 0.70 331.6 3.48 1.67 48.07 
LCPUFA 9.30 2.85 30.61 5.04 2.14 42.57 13.87 3.49 25.16 
LC/SM 0.16 0.06 36.23 0.09 0.05 50.99 0.23 0.07 29.07 
ED/SM 0.03 0.02 67.86 0.004 0.01 323.7 0.05 0.03 61.06 
AA/SM 0.12 0.05 36.77  0.09 0.04 49.79  0.15 0.04 28.50 
Abbreviations: AA, 20:4n-6; TOTS, total saturated; TOTM, total monounsaturated; POLY, total polyunsaturated; 
TN6, total n-6 PUFA; TN3, total n-3 PUFA; N6LC, total long-chain n-6 PUFA (20C and 22C); N3LC, total long-
chain n-3 PUFA (20C and 22C); LCPUFA, the sum of N6LC and N3LC; LC/SM, LCPUFA/(TOTS + TOTM); 
ED/SM, (EPA + DHA)/(TOTS + TOTM); AA/SM, AA/(TOTS + TOTM); ND, not detected, below detection limit 
of 10 ng/peak.   
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Table 4.  Relationship between clinical parameters and fatty acids in serum polar lipid fraction  
measurements 
 Survived (n = 300) Deceased (n = 100) T-test p 
value  Mean SD Mean SD 
BMI  26.43 6.77  25.45 6.73 0.21 
SBP  144 21  139 27 0.074 
DBP  73 12  72 14 0.62 
CHOL  152 44  147 52 0.5 
18: 2n-6  18.66 2.80  18.63 2.76 0.92 
20: 4n-6  10.81 2.43  9.48 2.37 <.0001 
20: 5n-3  0.37 0.36  0.31 0.47 0.27 
22: 6n-3  3.01 1.02  2.47 1.21 0.0001 
TOTS  40.76 2.84  41.15 3.34 0.29 
TOTM  19.34 3.78  20.93 4.18 0.004 
POLY  37.29 2.80  35.21 3.49 <.0001 
TN6  32.76 2.45  31.38 3.00 <.0001 
TN3  4.53 1.31  3.83 1.65 0.0002 
TN6/TN3  7.76 2.04  9.08 2.67 <.0001 
N6LC  11.74 2.55  10.39 2.55 <.0001 
N3LC  4.16 1.33  3.48 1.67 0.0003 
LCn6/LCn3  2.99 0.75  3.26 0.90 0.0065 
LCPUFA  15.90 3.30  13.87 3.49 <.0001 
LC/SM  0.27 0.06  0.23 0.07 <.0001 
ED/SM  0.06 0.02  0.05 0.03 0.0042 
AA/SM  0.18 0.04  0.15 0.04 <.0001 
Abbreviations: TOTS, total saturated; TOTM, total monounsaturated; POLY, total 
polyunsaturated; TN6, total n-6 PUFA; TN3, total n-3 PUFA; N6LC, total long-chain n-6 PUFA 
(20C and 22C); N3LC, total long-chain n-3 PUFA (20C and 22C); LCPUFA, the sum of N6LC 
and N3LC; LC/SM, LCPUFA/(TOTS + TOTM); ED/SM, (EPA + DHA)/(TOTS + TOTM);  
AA/SM, AA/(TOTS + TOTM).  
 
BMI: body mass index.   
SBP: Average of pre-treatment sitting systolic blood pressures 
DBP: Average of pre-treatment sitting diastolic blood pressures 
CHOL: baseline cholesterol  
Fatty acids and ratios are for polar lipids FAME.   
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Table 5.  Correlations between fatty acids in serum total lipid, polar lipid or neutral lipid and 
blood pressure (SBP and DBP) and cholesterol levels 
 
 
 
Fatty acids 
 
 
SBP (n = 400) 
Correlation coefficient (r) 
 
DBP (n = 400) 
 
 
Cholesterol (n = 272) 
Total Polar Neutral Total Polar Neutral Total Polar Neutral 
18: 2n-6       0.232 0.177 0.204 
       [0.0001] [0.003] [0.0007] 
20: 4n-6  0.110  0.114     
  [0.028]  [0.023]     
20: 5n-3 0.115 0.111 0.102  0.120 0.137 0.165 
 [0.022] [0.027] [0.042]  [0.047] [0.024] [0.0065] 
22: 6n-3  0.135 0.122   0.200 0.352 
  [0.007] [0.015]     [0.0009] [<.0001] 
TOTS        -0.158  
      [0.009]  
TOTM  -0.105 -0.103  -0.209 -0.144 -0.184 
  [0.036] [0.039]  [0.0005] [0.017] [0.0023] 
POLY  0.135 0.102  0.181 0.284 0.245 
  [0.007] [0.042]    [0.003] [<.0001] [<.0001] 
TN6       0.16608 0.217 0.196 
       [0.006] [0.0003] [0.0012] 
TN3 0.113 0.158 0.152  0.120 0.231 0.388  [0.024] [0.002] [0.002]  [0.047] [0.0001] [<.0001] 
TN6/TN3  -0.142    -0.182    [0.005]    [0.003]  
N6LC  0.107  0.117       [0.032]  [0.020]     
N3LC 0.103 0.151 0.124   0.213 0.302 
 [0.039] [0.003] [0.013]     [0.0004] [<.0001] 
LCn6/LCn3        -0.187  
      [0.002]  
LCPUFA  0.145 0.118 0.125   0.124 0.142 
  [0.004] [0.018] [0.013]   [0.040] [0.019] 
LC/SM  0.156 0.108 0.128   0.168 0.158 
  [0.002] [0.031] [0.010]   [0.006] [0.009] 
ED/SM 0.099 0.150 0.119  0.124 0.225 0.311 
 [0.048] [0.003] [0.017]  [0.041] [0.0002] [<.0001] 
AA/SM  0.124  0.119     
  [0.013]  [0.017]     
# of p < 0.05 4 13 9 0 5 0 7 14 11 
Data in the row following the fatty acid are correlation coefficient (r) and the numbers in 
brackets in the lower row below the correlation coefficient are p values. 
Only significant values are shown, all non-significant values are not shown.   
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure, TOTS, total 
saturated; TOTM, total monounsaturated; POLY, total polyunsaturated; TN6, total n-6 PUFA; 
TN3, total n-3 PUFA; N6LC, total long-chain n-6 PUFA (20C and 22C); N3LC, total long-chain 
n-3 PUFA (20C and 22C); LCPUFA, the sum of N6LC and N3LC; LC/SM, LCPUFA/(TOTS + 
TOTM); ED/SM, (EPA + DHA)/(TOTS + TOTM);  AA/SM, AA/(TOTS + TOTM). 
